TY - JOUR
T1 - Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT
AU - Hernández Vara, Jorge
AU - del Fueyo, Marta Rubiera
AU - Lorenzo Bosquet, Carles
AU - Castell Conesa, Joan
AU - Molina Cateriano, Carlos A.
AU - Miquel Rodríguez, Francisco
PY - 2008/9/13
Y1 - 2008/9/13
N2 - Background and objective: An increased echogenicity of the substantia nigra in patients with Parkinson's disease has been demonstrated by brain parenchyma sonography (BPS). BPS is a new and non-invasive technique that allows imaging of the brain in 2-dimensional axial slices. Changes in echogenicity can be displayed using ultrasounds. The aim of this study is to evaluate substantia nigra echogenicity in a group of Parkinson's disease patients and controls and compare with disease and functional neuroimaging parameters using ioflupane-single photon emission computed tomography (SPECT). Patients and method: Fourty-two subjects were recruited consecutively. BPS and ioflupane-SPECT were performed in all. Results: Around 90% of Parkinson's disease patients showed a distinctive increase of echogenicity of substantia nigra above or equal 0.18 cm2, whereas this echo feature was detected in 11% of controls. Most of patients (86%) with an area of substantia nigra echogenicity above or equal 0.18 cm2 showed a nigro-striatal impairment, that is, a decreased ioflupane uptake measured by SPECT. Conclusions: BPS is a useful tool in the diagnosis of Parkinson's disease. A good agreement between both techniques was achieved. The diagnosis accuracy obtained using BPS does not seem superior to ioflupane-SPECT. Nevertheless, hyperechogenicity could be considered as a vulnerability «marker» of the substantia nigra. © 2008 Elsevier España S.L. All rights reserved.
AB - Background and objective: An increased echogenicity of the substantia nigra in patients with Parkinson's disease has been demonstrated by brain parenchyma sonography (BPS). BPS is a new and non-invasive technique that allows imaging of the brain in 2-dimensional axial slices. Changes in echogenicity can be displayed using ultrasounds. The aim of this study is to evaluate substantia nigra echogenicity in a group of Parkinson's disease patients and controls and compare with disease and functional neuroimaging parameters using ioflupane-single photon emission computed tomography (SPECT). Patients and method: Fourty-two subjects were recruited consecutively. BPS and ioflupane-SPECT were performed in all. Results: Around 90% of Parkinson's disease patients showed a distinctive increase of echogenicity of substantia nigra above or equal 0.18 cm2, whereas this echo feature was detected in 11% of controls. Most of patients (86%) with an area of substantia nigra echogenicity above or equal 0.18 cm2 showed a nigro-striatal impairment, that is, a decreased ioflupane uptake measured by SPECT. Conclusions: BPS is a useful tool in the diagnosis of Parkinson's disease. A good agreement between both techniques was achieved. The diagnosis accuracy obtained using BPS does not seem superior to ioflupane-SPECT. Nevertheless, hyperechogenicity could be considered as a vulnerability «marker» of the substantia nigra. © 2008 Elsevier España S.L. All rights reserved.
KW - Diagnostic accuracy
KW - Ioflupane
KW - Parkinson's disease
KW - Substantia nigra hyperechogenicity
KW - Transcranial ultrasound
U2 - 10.1157/13125786
DO - 10.1157/13125786
M3 - Article
SN - 0025-7753
VL - 131
SP - 285
EP - 289
JO - Medicina Clinica
JF - Medicina Clinica
IS - 8
ER -